title: C5L2 is a functional receptor for acylation-stimulating protein.
abstract: C5L2 binds acylation-stimulating protein (ASP) with high affinity and is expressed in ASP-responsive cells. Functionality of C5L2 has not yet been demonstrated. Here we show that C5L2 is expressed in human subcutaneous and omental adipose tissue in both preadipocytes and adipocytes. In mice, C5L2 is expressed in all adipose tissues, at levels comparable with other tissues. Stable transfection of human C5L2 cDNA into HEK293 cells results in ASP stimulation of triglyceride synthesis (TGS) (193 +/- 33%, 5 microM ASP, p < 0.001, where basal = 100%) and glucose transport (168 +/- 21%, 10 microM ASP, p < 0.001). C3a similarly stimulates TGS (163 +/- 12%, p < 0.001), but C5a and C5a des-Arg have no effect. The ASP mechanism is to increase Vmax of glucose transport (149%) and triglyceride (TG) synthesis activity (165%) through increased diacylglycerolacyltransferase activity (200%). Antisense oligonucleotide down-regulation of C5L2 in human skin fibroblasts decreases cell surface C5L2 (down to 54 +/- 4% of control, p < 0.001, comparable with nonimmune background). ASP response is coordinately lost (basal TGS = 14.6 +/- 1.6, with ASP = 21.0 +/- 1.4 (144%), with ASP + oligonucleotides = 11.0 +/- 0.8 pmol of TG/mg of cell protein, p < 0.001). In mouse 3T3-L1 preadipocytes, antisense oligonucleotides decrease C5L2 expression to 69.5 +/- 0.5% of control, p < 0.001 (comparable with nonimmune) with a loss of ASP stimulation (basal TGS = 22.4 +/- 2.9, with ASP = 39.6 +/- 8.8 (177%), with ASP + oligonucleotides = 25.3 +/- 3.0 pmol of TG/mg of cell protein, p < 0.001). C5L2 down-regulation and decreased ASP response correlate (r = 0.761, p < 0.0001 for HSF and r = 0.451, p < 0.05 for 3T3-L1). In HEK-hC5L2 expressing fluorescently tagged beta-arrestin, ASP induced beta-arrestin translocation to the plasma membrane and formation of endocytic complexes concurrently with increased phosphorylation of C5L2. This is the first demonstration that C5L2 is a functional receptor, mediating ASP triglyceride stimulation.
authors.affiliation: Mike Rosenbloom Laboratory for Cardiovascular Research, Division of Cardiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec H3A 1A1, Canada.
authors.forename: David
authors.initials: D
authors.lastname: Kalant
authors.forename: Robin
authors.initials: R
authors.lastname: MacLaren
authors.forename: Wei
authors.initials: W
authors.lastname: Cui
authors.forename: Ratna
authors.initials: R
authors.lastname: Samanta
authors.forename: Peter N
authors.initials: PN
authors.lastname: Monk
authors.forename: Stephane A
authors.initials: SA
authors.lastname: Laporte
authors.forename: Katherine
authors.initials: K
authors.lastname: Cianflone
mesh_terms: D000818:Animals; D019393:Arrestin / Q000378:metabolism; D001483:Base Sequence; D002460:Cell Line; D015926:Complement C3a / Q000378:metabolism*; D017931:DNA Primers; D018076:DNA, Complementary; D006801:Humans; D051379:Mice; D011485:Protein Binding; D012333:RNA, Messenger / Q000235:genetics; D044087:Receptor, Anaphylatoxin C5a; D019707:Receptors, Chemokine / Q000235:genetics / Q000378:metabolism*
chemical_list: D019393:Arrestin; C417003:C5aR2 protein, human; D017931:DNA Primers; D018076:DNA, Complementary; D012333:RNA, Messenger; D044087:Receptor, Anaphylatoxin C5a; D019707:Receptors, Chemokine; C044541:complement C3a, des-Arg-(77)-; D015926:Complement C3a